Oligometastatic tumor of lung
Conditions
Interventions
experimental group:Radiotherapy combined with anti-PD-1 therapy
Sponsors
The First Affiliated Hospital of Bengbu Medical College
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1. Age: >= 18 years old, male or female; 2. The primary tumor should be confirmed by pathology or histology, the number of oligometastatic organs in the lung is not more than 3, and the total number of metastatic lesions is not more than 5. And the diagnosis of pulmonary oligometastasis is at least confirmed by imaging evidence or pathology. And at least one measurable lesion (helical CT scan >=10mm, conform the RECIST 1.1 standard); 3. If accompanied by other site metastasis, it is necessary to meet the definition of oligodeoxynucleotide metastasis, and there are no more than 3 metastatic organs; 4. Patients without intracranial and meningeal metastases were confirmed by cranial MRI enhancement; 5. The ECOG score of the patients was 0-2, while the KPS score was 70; 6.expected survival more than three months; 7. The function of the main organs is normal, and the blood routine examination and biochemical examination meet the general requirements of radiotherapy and chemotherapy. 8. The subjects voluntarily joined the study and signed an informed consent form with good compliance and follow-up.
Exclusion criteria
Exclusion criteria: 1. Pregnant or lactating; 2. Patients have previous immune-related diseases, such as rheumatoid arthritis, psoriasis, systemic lupus erythematosus, etc. 3. Those who receive hormone therapy such as AIDS, hepatitis C, hepatitis B infection; 4. Patients with meningeal metastasis or worsening brain metastasis; 5. Patients who have received allotransplantation and immunosuppressive therapy; 6. Patients with interstitial pneumonia; 7. Patients with severe hepatorenal insufficiency, cardiac insufficiency and severe hypertension and diabetes mellitus; 8. The other above are not included, but the patients who have been jointly evaluated by the researchers are not suitable for this study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Overall survival; | — |
Secondary
| Measure | Time frame |
|---|---|
| Objective response rate;Progression Free Survival;Disease control rate;The quality of life;Observation on adverse events of radiotherapy and drug use; | — |
Countries
China
Contacts
Public ContactHao jiang
The First Affiliated Hospital of Bengbu Medical College
Outcome results
None listed